PP-01 is under clinical development by Pleopharma and currently in Phase III for Substance (Drug) Abuse. According to GlobalData, Phase III drugs for Substance (Drug) Abuse have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how PP-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PP-01 overview
PP-01 is under development for the treatment of an unspecified central nervous system disorder and cannabis withdrawal symptoms. The drug candidate is administered through oral route.
Pleopharma overview
Pleopharma focuses on development of treatments in the field of CNS and substance abuse space. Pleopharma is headquartered in Phoenixville, Pennsylvania, the US.
For a complete picture of PP-01’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
